Develops novel peptide-based therapeutics that modulate immune responses to correct dysfunctional healing by controlling microbial presence and inflammatory pathways. Advancing TCP25 in clinical development (phase 1b for epidermolysis bullosa) and pursuing late-stage development and commercialization through partnerships with pharmaceutical companies.